Download presentation
Presentation is loading. Please wait.
Published byJean-Baptiste Rancourt Modified over 6 years ago
1
Disease specific databases for personalized medicine: Fabry disease as a case of study
Maria Vittoria Cubellis Dipartimento di Biologia , Università Federico II, Napoli, Italia 7th International Conference on Proteomics & Bioinformatics Rome, October 24-26, 2016.
2
Lysosomal alpha-galactosidase
429 aa 31 aa signal peptide 5 disulphide bridges 3 glycosylation sites homodimer 17 X-ray structures
5
Endoplasmic reticulum
Autophagy Golgi apparatus Autophagosome Phagocytosis Primary lysosomes exocytosis Secondary lysosomes Exocytosis Late endosome Residual bodies endocytosis Early endosome
6
Endoplasmic reticulum
Autophagy Golgi apparatus Autophagosome Phagocytosis Primary lysosomes exocytosis Secondary lysosomes Exocytosis Late endosome Residual bodies endocytosis Early endosome
7
GLA is located on X chromosome
8
wide spectrum of heterogeneously clinical phenotypes Progressive
FABRY DISEASE wide spectrum of heterogeneously clinical phenotypes Progressive Multiple organ systems Morbidity Cardiac complications Stroke Renal failure Decreased lifespan
11
Enzymatic replacement therapy
ERT
12
ERT versus PC Enzyme replacement therapy ERT
High cost Intravenous Infusion Does not reach CNS Immune reaction Therapy with pharmacological chaperones(PC) Low cost Oral administration Reaches CNS
13
ΔG (PROTEIN+CHAPERONE)= ΔG(PROTEIN) +RTln(1+CHAPERONE/Kd)
CHAPERONES ARE LIGANDS WHICH PREFERENTIALLY BIND THE FOLDED STATE OF PROTEINS CHAPERONE UNFOLDED WT PROTEIN FOLDED WT PROTEIN ΔG (PROTEIN+CHAPERONE)= ΔG(PROTEIN) +RTln(1+CHAPERONE/Kd)
14
DESTABILIZING MUTATIONS LOWER THE FREE ENERGY DIFFERENCE BETWEEN NATIVE AND UNFOLDED MUTANTS
ΔGN→D=1 D A288P mildly destabilizing ΔGN→D=8 ΔGN→D=10 F50C severely destabilizing N wild
15
ΔG (PROTEIN+CHAPERONE)= ΔG(PROTEIN) +RTln(1+CHAPERONE/Kd)
CHAPERONES ARE LIGANDS WHICH PREFERETIALLY BIND THE FOLDED STATE OF SOME MUTANT PROTEINS CHAPERONE UNFOLDED MUTANT FOLDED MUTANT ΔG (PROTEIN+CHAPERONE)= ΔG(PROTEIN) +RTln(1+CHAPERONE/Kd)
16
UNFOLDING FOLDING PROTEASOME
17
Total amount of mutant A-Gal is lower than wild type in cells, but is increased by PC
WITHOUT CHAPERONE - WITH CHAPERONE + FIBROBLASTS FROM PATIENTS OR TRASFECTED MUTANTS WESTERN BLOT ALPHA GALACTOSIDASE
18
WESTERN BLOT ANALYSIS
19
ACTIVITY ASSAY -DGJ +DGJ 20 MICROMOLAR
21
One subunit of lysosomal alpha-galactosidase
22
Almost all amino-acids can be mutated
23
Some mutations retain residual activity
No residual activity Some residual activity
24
Some mutations retain enzymatic activity
More than 500 missense mutations*, mostly private, are known for Fabry diseases Some mutations retain enzymatic activity *
25
Some mutations respond to pharmacological chaperones
Responsive Non responsive
27
Mutations affecting disulphide bridges do not retain residual activity in vivo and do not respond to chaperones
28
Mutations affecting the active site do not retain residual activity in vivo and do not respond to chaperones
29
Severely destabilizing mutations do not retain residual activity in vivo and do not respond to chaperones ΔGN→D=5 F50C severely destabilizing
32
FLEXIBILITY AND RESIDUAL ACTIVITY CORRELATE
33
OUTLIERS ARE MOSTLY GLYCINES
34
Mutations affecting the active site or disulphide bridges as well as severely destabilizing mutations, which prevent folding, do not retain residual activity Mutations occurring at very rigid sites do not retain residual activity. Residual activity correlates with flexibility
36
Assignment of PSSM scores to A-gal mutants
Let’s consider two cases: N122D and N139D
37
P S S M O P U A S E B T I C S R T I T I I F I X O I T N C U T I O N
38
PSSM SCORES CORRELATE WITH RESPONSIVENESS
% Responsive (GALAFOLD)
41
Mutations occurring at non conserved sites retain residual activity and are responsive to chaperones
43
Residual activity in vitro of putative non pathological a-gal
mut N hemiz -DGJ +DGJ PSSM humdiv E66Q 3 47.6 53.66 -2 Probably damaging R118C 8 24.5 27.8 S126G 18 51.3 67.4 benign A143T 19 39.7 63.7 -1 D313Y 129 75.5 100.3 R363H 28 65.7 T385A 36 45 48.9 Possibly damaging W399S 5 53 51.5 -4
44
Mutations retaining >25% residual activity might be considered non pathological variants
45
I would like to thank: Dr G.Andreotti who is responsible for the experiments in vitro Dr V.Citro who is responsible for the experiments with cells M.Cammisa for develping Fabry_CEP Telethon for funding us
46
References Andreotti G, Guarracino M.R., Marco Cammisa M., Antonella Correra A., Cubellis MV. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. Orphanet Journal of Rare Diseases, 2010, 5:36 Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests. Orphanet J Rare Dis :66 Cammisa M, Correra A, Andreotti G, Cubellis MV. Identification and analysis of conserved pockets on protein surfaces. BMC Bioinformatics. 2013; 14 Suppl 7:S9 Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones. Orphanet J Rare Dis :111 Andreotti G, Citro V, Correra A, Cubellis MV. A thermodynamic assay to test pharmacological chaperones for Fabry disease. Biochim Biophys Acta ;1840: Cubellis MV, Baaden M, Andreotti G. Taming molecular flexibility to tackle rare diseases. Biochimie Apr 2. pii: S (15) doi: /j.biochi [Epub ahead of print] Andreotti G, Monticelli M, Cubellis MV. Looking for protein stabilizing drugs with thermal shift assay. Drug Test Anal Apr 5. doi: /dta [Epub ahead of print] HayMele B, Citro V, Andreotti G., Cubellis MV Drug repositioning can accelerate discovery of pharmacological chaperones. Orphanet J Rare Dis May 7;10(1):55. doi: /s .
47
Palazzo Donn’Anna, Posillipo, Napoli
Thank you for your attention Palazzo Donn’Anna, Posillipo, Napoli
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.